Alasdair Thong

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From licensing our platforms, to working with us as a trusted discovery service partner, we have collaborated with over 170+ partners and counting including 18 of Fortune 50 Biopharmaceutical companies to enable the discovery of their next breakthrough biologic medicines. With Alloy, you can: • Access our ever-growing stable of antibody and bispecific discovery platforms that blend in vivo and in vitro wet-lab capabilities with AI/ML. Discover with us through our services or by licensing our technologies for use in your lab. • Unlock intracellular targets with the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated Keyway™ TCRm discovery service offering. • Reach genetic disease targets at the nucleic acid level with our novel AntiClastic™ ASO Format, which enhances the molecules potency while minimizing off-target interaction and inflammatory response. • Co-build new biotechnology companies that leverage our core platforms and service capabilities with Alloys affiliated Venture Studio, 82VS. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K.; Basel, CH; and Athens, GA. We reinvest 100% of our revenue back into innovation and access to innovation. Reach out, follow, and visit our website, to learn more about how we can make better medicines, together. https://www.alloytx.com/

The Ellison Institute of Technology develops and deploys technology in pursuit of solving four of humanity’s most challenging and enduring problems. Guided by world leaders, scientists and entrepreneurs, EIT seeks to accelerate innovation in medical science and healthcare, food security and sustainable agriculture, clean energy and climate change, and government policy and economics.

EIT Oxford’s mission is to discover, develop and deploy science and technology in pursuit of solving some of humanity’s most challenging and enduring problems. Guided by world leaders, scientists and entrepreneurs, EIT seeks to accelerate innovation in health and medical science, food security and sustainable agriculture, climate change and clean energy, and government innovation in an era of artificial intelligence. Set for completion in 2027, the new EIT Oxford campus will incorporate more than 30,000m2 of research laboratory space, an oncology and preventative care clinic, and educational and gathering spaces to support ongoing work in EIT’s humane endeavours. The facility’s location on the Oxford Science Park will further EIT’s current partnerships in the Oxford biotech and technology communities, expand collaborations with the University of Oxford, and support the new Ellison Scholars programme. Contact us: oxford@eit.org or oxfordpress@eit.org

Metsera is now part of Pfizer! Together with our Pfizer colleagues, we will continue our mission to advance the next generation of medicines for obesity and cardiometabolic diseases. Learn more here: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-metsera Metsera social media accounts, including this page, will no longer be active or monitored. Please follow Pfizer for updates: https://www.linkedin.com/company/pfizer/

Ollin Biosciences is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology.

Medical device/biopharmaceutical startup developing medicated stickers capable of delivering antihistamines and other small molecules to children. Target markets: Children, elderly, bariatric patients, dysphagia sufferers Part of the Velocity Incubator, Communitech network, and Bayer Grants4Apps accelerator

BIOS Health uses AI-driven insights from the nervous system to build neural digital therapies - the next big trend in precision medicines. The human nervous system carries vast quantities of data, and BIOS’ ability to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is a game changer for precision medicine. BIOS’ research could hold the key to new treatments for conditions including hypertension, diabetes, rheumatoid arthritis, and even diseases of the brain itself such as Parkinson’s or Alzheimer’s. BIOS is positioned to provide the neural code on which a new generation of treatments can be built that can enable millions of people suffering from chronic diseases to improve their quality of life. Co-founded by Cambridge University researchers Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology, medicine, and business and operations. The combined experience of the BIOS team extends to over 300 peer-reviewed publications, 10+ first of kind medical devices, and 6k+ clinical procedures. We are looking for people who will fit into our diverse, fun and stimulating company team culture, who are focused on overcoming challenges, and want to grow along with the company. We are especially looking for candidates that share our values: enjoy solving hard problems; bring a unique perspective but become an active part of the BIOS team; respect what matters and do what’s right; and enjoy the challenge.

CCX empowers you to plan, negotiate, and administer deals on your terms, with a simple and configurable infrastructure. Our proven technology delivers your strategy, and better outcomes.

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com.

Exogene is an Oxford-based, venture-backed biotechnology company using a proprietary lab-in-the-loop AI platform to design novel, multi-specific immune engager drugs targeting peptide-HLA antigens to eradicate cancer.

UniTartu Ventures collaborates with early-stage deep tech investors and researchers, startups, and spin-offs linked to the University of Tartu, aiming to transform university research into thriving businesses. UniTartu Ventures provides a structured pathway to support spin-offs in achieving investment readiness: - Offers mentorship focusing on business expansion and team collaboration. - Assists in developing strategies for the effective protection and utilization of intellectual property. - Prepares startups for investment opportunities. - Attracts committed co-investors for sustained success. - Our approach involves investing in university research through an IP-for-equity model, guaranteeing that innovative ideas receive the necessary support.

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From licensing our platforms, to working with us as a trusted discovery service partner, we have collaborated with over 170+ partners and counting including 18 of Fortune 50 Biopharmaceutical companies to enable the discovery of their next breakthrough biologic medicines. With Alloy, you can: • Access our ever-growing stable of antibody and bispecific discovery platforms that blend in vivo and in vitro wet-lab capabilities with AI/ML. Discover with us through our services or by licensing our technologies for use in your lab. • Unlock intracellular targets with the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated Keyway™ TCRm discovery service offering. • Reach genetic disease targets at the nucleic acid level with our novel AntiClastic™ ASO Format, which enhances the molecules potency while minimizing off-target interaction and inflammatory response. • Co-build new biotechnology companies that leverage our core platforms and service capabilities with Alloys affiliated Venture Studio, 82VS. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K.; Basel, CH; and Athens, GA. We reinvest 100% of our revenue back into innovation and access to innovation. Reach out, follow, and visit our website, to learn more about how we can make better medicines, together. https://www.alloytx.com/

The Ellison Institute of Technology develops and deploys technology in pursuit of solving four of humanity’s most challenging and enduring problems. Guided by world leaders, scientists and entrepreneurs, EIT seeks to accelerate innovation in medical science and healthcare, food security and sustainable agriculture, clean energy and climate change, and government policy and economics.

EIT Oxford’s mission is to discover, develop and deploy science and technology in pursuit of solving some of humanity’s most challenging and enduring problems. Guided by world leaders, scientists and entrepreneurs, EIT seeks to accelerate innovation in health and medical science, food security and sustainable agriculture, climate change and clean energy, and government innovation in an era of artificial intelligence. Set for completion in 2027, the new EIT Oxford campus will incorporate more than 30,000m2 of research laboratory space, an oncology and preventative care clinic, and educational and gathering spaces to support ongoing work in EIT’s humane endeavours. The facility’s location on the Oxford Science Park will further EIT’s current partnerships in the Oxford biotech and technology communities, expand collaborations with the University of Oxford, and support the new Ellison Scholars programme. Contact us: oxford@eit.org or oxfordpress@eit.org

Metsera is now part of Pfizer! Together with our Pfizer colleagues, we will continue our mission to advance the next generation of medicines for obesity and cardiometabolic diseases. Learn more here: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-metsera Metsera social media accounts, including this page, will no longer be active or monitored. Please follow Pfizer for updates: https://www.linkedin.com/company/pfizer/